search
Back to results

Legalon SIL for the Treatment of HCV Recurrence in Liver Transplanted Patients

Primary Purpose

HCV Recurrence After Liver Transplantation

Status
Terminated
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
Silibinin
Placebo
Sponsored by
Rottapharm
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for HCV Recurrence After Liver Transplantation focused on measuring HCV recurrence, HCV reinfection, Liver transplantation, Legalon SIL, silibinin, viral load

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Patient must provide signed and dated informed consent before undergoing any trial related procedure.
  2. Patient between 18 and 70 years of age.
  3. Patient must have documented HCV infection. The HCV-RNA result obtained from the local laboratory at the screening visit must confirm HCV-RNA > 1000 IU/mL.
  4. Patient must qualify for liver transplantation at the time of Screening according to Model for End stage Liver Disease (MELD) criteria
  5. Patient must have a documented diagnosis of cirrhosis.
  6. Patient weigh between 50 kg and 100 kg.
  7. Patients must be able to communicate, participate and comply with the requirements of the entire study.
  8. Female patients of child-bearing potential must agree on using a contraceptive method (oral contraceptive, intrauterine device, transdermal contraceptive patch) and must have a negative pregnancy urine test at screening.
  9. HCV Genotype, chest X-ray, ultrasonography and ocular examination (for patients with history of diabetes or hypertension) must be performed within 6 months prior to Screening or between Screening and Day 1. 12-Lead ECG must be performed within 3 months prior to Screening.

Exclusion Criteria:

  1. Patients known to be coinfected with the human immunodeficiency virus (HIV) or hepatitis B virus (HBsAg positive).
  2. Active septic infections at time of screening.
  3. Previous organ transplantation other than cornea and hair.
  4. Use of systemic immunosuppressant or immunomodulating agents (including systemic corticosteroids) within 4 weeks of the screening visit or during the screening period.
  5. Treatment for HCV with any investigational medication (prior use of silymarin is not exclusionary)
  6. Treatment for HCV with any licensed therapies or prior maintenance therapy with any interferon alpha within 30 days of the randomization visit.
  7. Participation in any other clinical trial within 30 days of randomization or intention to participate in another clinical trial during participation in this study.
  8. Any known pre-existing medical condition that could interfere with the subject's participation in and completion of the study including but not limited to:

    • Chronic pulmonary disease (eg, clinical chronic obstructive pulmonary disease, interstitial lung disease, pulmonary fibrosis, sarcoidosis).
    • Current or history of any clinically significant cardiac abnormalities/dysfunction (eg, angina, congestive heart failure, myocardial infarction, pulmonary hypertension, complex congenital heart disease, cardiomyopathy, significant arrhythmia) including current uncontrolled hypertension, or history of use of antianginal agents for cardiac conditions.
    • Any other condition which, in the opinion of a physician-investigator, would make the patient unsuitable for enrollment or could interfere with the subject participating in and completing the study.
  9. Subjects who are part of the site personnel directly involved with this study or those who are family members of the investigational study staff.
  10. If female, pregnancy or breast-feeding.
  11. Known hypersensitivity to Legalon® SIL.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Placebo Comparator

    Arm Label

    silibinin

    Placebo

    Arm Description

    Silibinin 20mg/Kg/day (Legalon SIL) by intravenous infusion for 14-21 days before OLT and for 7 days after OLT

    Placebo (NaCl 0.9% - saline) administered daily by intravenous infusion for 14-21 days before OLT and 7 days after OLT

    Outcomes

    Primary Outcome Measures

    Sustained virological response (SVR), defined as Virological Response (undetectable HCV-RNA) that lasts 6 months after the transplant

    Secondary Outcome Measures

    Virologic response (VR) defined as undetectable HCV RNA
    Percentage of patients who has a decreased of at least 2 log10 the levels of HCV-RNA
    Number of patients with AE
    laboratory parameters
    blood levels of immunosuppressive drugs
    Vital signs
    ECG

    Full Information

    First Posted
    February 7, 2012
    Last Updated
    February 14, 2012
    Sponsor
    Rottapharm
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT01535092
    Brief Title
    Legalon SIL for the Treatment of HCV Recurrence in Liver Transplanted Patients
    Official Title
    A Randomized, Double-Blind, Placebo Controlled Study to Investigate the Efficacy and Safety of Legalon SIL for the Treatment of HCV Recurrence of the Graft in Orthotopic Liver Transplant Patients
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    February 2012
    Overall Recruitment Status
    Terminated
    Why Stopped
    when realized that the target 60% of patients with SVR was no more achievable
    Study Start Date
    September 2010 (undefined)
    Primary Completion Date
    October 2011 (Actual)
    Study Completion Date
    November 2011 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Rottapharm

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    Orthotopic liver transplantation (OLT) is the treatment of choice for patients with Hepatitis C Virus (HCV) infection and end-stage liver disease or hepatocellular carcinoma; infection of the graft and hepatitis C recurrence is universal after OLT and recurrent HCV hepatitis often follows an accelerated course after OLT, with rapid histological recurrence and cirrhosis. These very poor outcome significantly affect graft and patient survival and reduces the benefit of transplantation for this indication. Therapeutic strategies are not available; high viral load, high prevalence of genotype 1b and need of dose reduction of interferon and ribavirin because of the side effects or intolerance, together with the interference of immunosuppressive drugs, resulted in the vast majority of the patients in failure in obtaining viral eradication. Recently, Silibinin, has been studied and reported to be capable to act as potent antiviral agent in patients with HCV; it has been used successfully in a protocol of a 14 day intravenous infusion in previous non-responders to peginterferon/ribavirin therapy. In view of his postulated profile of safety, it seems an ideal drug to be used in the setting of HCV recurrent patients after liver transplant. Aim of this prospective, randomized, double-blind, placebo-controlled, parallel group study is to determine the therapeutic effect of Legalon SIL in the prevention of HCV reinfection in chronically infected hepatitis C patients after OLT. Awaiting orthotopic liver transplantation patients affected by HCV will be randomised 3:1 to receive, in addition to their current therapy, silibinin 20mg/kg/day (Legalon SIL) or placebo infused over 2 hours from 14 to 21 consecutive days; in addition, patients will receive treatment with silibinin 20mg/kg/day (Legalon SIL), infused over 2 hours, for 7 days after transplant. The Primary Efficacy endpoint is to achieve sustained virological response (SVR) while Secondary Efficacy endpoints are to evaluate the virologic response, the percentage of patients who has a decreased of at least 2 log10 the levels of HCV-RNA and the safety of Legalon SIL in this population.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    HCV Recurrence After Liver Transplantation
    Keywords
    HCV recurrence, HCV reinfection, Liver transplantation, Legalon SIL, silibinin, viral load

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 2
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantInvestigator
    Allocation
    Randomized
    Enrollment
    14 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    silibinin
    Arm Type
    Experimental
    Arm Description
    Silibinin 20mg/Kg/day (Legalon SIL) by intravenous infusion for 14-21 days before OLT and for 7 days after OLT
    Arm Title
    Placebo
    Arm Type
    Placebo Comparator
    Arm Description
    Placebo (NaCl 0.9% - saline) administered daily by intravenous infusion for 14-21 days before OLT and 7 days after OLT
    Intervention Type
    Drug
    Intervention Name(s)
    Silibinin
    Other Intervention Name(s)
    Legalon SIL
    Intervention Description
    20mg/Kg daily by intravenous infusion, for 14-21 days pre-OLT and for 7 days post-OLT
    Intervention Type
    Drug
    Intervention Name(s)
    Placebo
    Intervention Description
    Saline, daily infused for 14-21 days pre-OLT and for 7 days post-OLT
    Primary Outcome Measure Information:
    Title
    Sustained virological response (SVR), defined as Virological Response (undetectable HCV-RNA) that lasts 6 months after the transplant
    Time Frame
    6 months
    Secondary Outcome Measure Information:
    Title
    Virologic response (VR) defined as undetectable HCV RNA
    Time Frame
    after 14-21 days of pre-OLT and 7 days of post-OLT treatment; week 2, 3, 4, 8, 12, 24 after OLT
    Title
    Percentage of patients who has a decreased of at least 2 log10 the levels of HCV-RNA
    Time Frame
    at week 4 after OLT
    Title
    Number of patients with AE
    Time Frame
    after 14-21 days of pre-OLT and 7 days of post-OLT treatment; week 2, 3, 4, 8, 12, 24 after OLT
    Title
    laboratory parameters
    Time Frame
    after 14-21 days of pre-OLT and 7 days of post-OLT treatment; week 2, 3, 4, 8, 12, 24 after OLT
    Title
    blood levels of immunosuppressive drugs
    Time Frame
    week 1, 2, 3, 4, 8, 12, 24 after OLT
    Title
    Vital signs
    Time Frame
    after 14-21 days of pre-OLT and 7 days of post-OLT treatment; week 2, 3, 4, 8, 12, 24 after OLT
    Title
    ECG
    Time Frame
    after 14-21 days of pre-OLT and 7 days of post-OLT treatment; week 2, 3, 4, 8, 12, 24 after OLT

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    70 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Patient must provide signed and dated informed consent before undergoing any trial related procedure. Patient between 18 and 70 years of age. Patient must have documented HCV infection. The HCV-RNA result obtained from the local laboratory at the screening visit must confirm HCV-RNA > 1000 IU/mL. Patient must qualify for liver transplantation at the time of Screening according to Model for End stage Liver Disease (MELD) criteria Patient must have a documented diagnosis of cirrhosis. Patient weigh between 50 kg and 100 kg. Patients must be able to communicate, participate and comply with the requirements of the entire study. Female patients of child-bearing potential must agree on using a contraceptive method (oral contraceptive, intrauterine device, transdermal contraceptive patch) and must have a negative pregnancy urine test at screening. HCV Genotype, chest X-ray, ultrasonography and ocular examination (for patients with history of diabetes or hypertension) must be performed within 6 months prior to Screening or between Screening and Day 1. 12-Lead ECG must be performed within 3 months prior to Screening. Exclusion Criteria: Patients known to be coinfected with the human immunodeficiency virus (HIV) or hepatitis B virus (HBsAg positive). Active septic infections at time of screening. Previous organ transplantation other than cornea and hair. Use of systemic immunosuppressant or immunomodulating agents (including systemic corticosteroids) within 4 weeks of the screening visit or during the screening period. Treatment for HCV with any investigational medication (prior use of silymarin is not exclusionary) Treatment for HCV with any licensed therapies or prior maintenance therapy with any interferon alpha within 30 days of the randomization visit. Participation in any other clinical trial within 30 days of randomization or intention to participate in another clinical trial during participation in this study. Any known pre-existing medical condition that could interfere with the subject's participation in and completion of the study including but not limited to: Chronic pulmonary disease (eg, clinical chronic obstructive pulmonary disease, interstitial lung disease, pulmonary fibrosis, sarcoidosis). Current or history of any clinically significant cardiac abnormalities/dysfunction (eg, angina, congestive heart failure, myocardial infarction, pulmonary hypertension, complex congenital heart disease, cardiomyopathy, significant arrhythmia) including current uncontrolled hypertension, or history of use of antianginal agents for cardiac conditions. Any other condition which, in the opinion of a physician-investigator, would make the patient unsuitable for enrollment or could interfere with the subject participating in and completing the study. Subjects who are part of the site personnel directly involved with this study or those who are family members of the investigational study staff. If female, pregnancy or breast-feeding. Known hypersensitivity to Legalon® SIL.
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Xavier Forns, Dr
    Organizational Affiliation
    Hospital Clinic i Barcelona
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Learn more about this trial

    Legalon SIL for the Treatment of HCV Recurrence in Liver Transplanted Patients

    We'll reach out to this number within 24 hrs